Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases

Anifrolumab for the treatment of refractory chilblain lupus erythematosus

“… 2 In a randomized, double-blind, placebo-controlled study of 305 patients with moderate-to-severe SLE, the percentage of patients with a cutaneous lupus erythematosus disease area and severity index score of ≥10 who improved by ≥50% at week 52 was superior with both anifrolumab doses (300 mg: 63%; 1000 mg: 58%) as compared with placebo (31%). 2 Additionally, anifrolumab proved efficacious for patients with refractory CLE in multiple case reports 2 , 3 , 4 , 5 , 6 , 7 and in 2 small prospective studies, 8 , 9 one of which had a patient with CHLE. This patient with CHLE showed a clinically meaningful improvement by 3 months, consistent with the patients in our case report.…”

Rapid response of refractory subacute cutaneous lupus after single dose anifrolumab

“… 7 Here, we showcase the clinical utility of anifrolumab in SCLE, and offer it as promising therapeutic option for patients who have failed belimumab, which is also supported by several case series. 3 , 4 , 5 Additionally, its rapid efficacy can prevent the irreversible damage associated with longstanding CLE including dyspigmentation and scarring which negatively impacts emotions and functioning of patients. It is important to note that a long-term sustained response and risk of flare or rebound with cessation of anifrolumab is not fully known.…”

“…Several case series have shown dramatic improvement in refractory cutaneous disease for patients with discoid lupus erythematosus, however, its utility in subacute cutaneous lupus (SCLE) is sparsely reported. 3 , 4 , 5 We herein present a case of a patient with refractory SCLE that responded rapidly after single dose of anifrolumab.…”

Anifrolumab for Moderate and Severe Muco-Cutaneous Lupus Erythematosus: A Monocentric Experience and Review of the Current Literature

“…, THL (1), ACT To date, nine reports on the response to anifrolumab therapy in SLE patients with muco-cutaneous lesions have been published in the literature [2,3,[5][6][7][8][9][10][11]. In total 46 patients have been described, with a mean age of 38 years (SD = 9.3; ranging between 19 years and 75 years.…”

“…Up to 80% of patients with systemic lupus erythematosus (SLE) may develop muco-cutaneous lesions, and about 25% of SLE patients have muco-cutaneous involvement at time of diagnosis. Unfortunately, CLE and discoid lupus erythematosus (DLE) may have an important impact in the daily life of patients, since cutaneous lesions may induce atrophy, scars and dyspigmentation [1][2][3][4][5][6][7][8][9][10][11].…”